Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records.
Christopher F BellDaniel C GibbonsMyriam DrysdaleHelen J BirchEmily J LloydVishal PatelCorinne CarpenterKatherine CarlsonEdiz S CalayArjun PuranikTyler E WagnerJohn C O'HoroRaymund R RazonablePublished in: PloS one (2024)
There was no significant difference in the proportion of sotrovimab-treated and PS-matched untreated patients experiencing 29-day all-cause hospitalization or mortality, although significantly fewer sotrovimab-treated patients required intensive care unit admission or respiratory support.
Keyphrases
- end stage renal disease
- intensive care unit
- newly diagnosed
- ejection fraction
- chronic kidney disease
- electronic health record
- emergency department
- randomized controlled trial
- prognostic factors
- systematic review
- cardiovascular disease
- cardiovascular events
- risk factors
- type diabetes
- coronary artery disease
- extracorporeal membrane oxygenation
- patient reported
- clinical decision support
- adverse drug